Bionano Genomics announces Iss –

SAN DIEGO, June 29, 2022 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (BNGO), today announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,359,244 on June 14, 2022 The patent, titled “CHARACTERIZATION OF MOLECULES IN NANOFLUIDICS,” claims methods for analyzing small nucleic acid fragments in nanochannel arrays, which Bionano has traditionally used to analyze ultra-high molecular weight (UHMW) DNA. for the identification of structural variants (SV) within the framework of its Saphyr® system. The methods claim the use of certain nanochannel arrays to detect and quantify genetic abnormalities, including translocation, amplification, transversion, inversion, aneuploidy, polyploidy, monosomy, trisomy, trisomy 21, trisomy 13, trisomy 14, trisomy 15, trisomy 16, trisomy 18, trisomy 22, triploidy, tetraploidy and aneuploidy of the sex chromosomes.

Nanochannel arrays have the potential to enable single molecule assays for circulating DNA found in blood and other fluid samples, which tend to be highly fragmented with average lengths between 150 and 200 base pairs. . Bionano believes that the methods described in the ‘244 patent could one day support the commercialization of assays for non-invasive prenatal testing (NIPT) in maternal-fetal medicine or cDNA in oncology.

The patent is part of Bionano’s intellectual property portfolio which includes several patents covering its core technology of confining and linearizing ultra-long DNA and other macromolecules in networks of parallel nanochannels, and the detection of sequences specific to characteristics or genomic markers on these molecules. Additionally, Bionano’s portfolio includes patents covering methods for manufacturing nanochannel devices, as well as other technologies for sample processing and analysis-related workflows.

“At Bionano, we remain committed to expanding the utility of our nanochannel arrays and building a strong patent portfolio that protects these applications. This patent is an exciting example of technology that could prove useful in creating new applications in important areas of medicine,” commented Erik Holmlin, PhD, President and CEO of Bionano Genomics.

About Bionano Genomics

Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to find answers to complex questions in biology and medicine. The company’s mission is to transform the way the world views the genome through GMO solutions, diagnostic services and software. The company offers GMO solutions for applications in basic, translational and clinical research. Through its Lineagen business, the company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorders and other neurodevelopmental disorders. Through its BioDiscovery business, the company also offers a cutting-edge, platform-independent software solution that integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and a report of copy number variants, single nucleotide variants and absence of heterozygosity across the genome in a consolidated view. For more information, visit, Where

Bionano Genomics Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “potential”, “believe” and similar expressions (as well as other words or expressions referring to future events, conditions or circumstances) convey uncertainty of future events or results and are intended to identify such forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, prospects, analyzes or current expectations regarding, among other things, the expected benefits and improvements resulting from the methods described in this patent, and the ability of the tools we could develop provide new knowledge on circulating nucleic acids for applications directed to NIPT in maternal-fetal medicine or ctDNA in oncology. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied by such forward-looking statements. Factors that could cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or enhancements to existing technologies; changes in our strategic and business plans; our ability to obtain sufficient financing to fund our strategic plans and marketing efforts; the ability of medical and research institutions to obtain funding to support the adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition generally, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on form 10-K for the year ended December 31, 2021 and in other filings subsequently filed by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date they were made and are based on management’s assumptions and estimates as of that date. We undertake no obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
[email protected]

Investor Relations:
Amy Conrad
tip of the juniper
+1 (858) 366-3243
[email protected]


Comments are closed.